Kamada (KMDA) to Release Quarterly Earnings on Wednesday

Kamada (NASDAQ:KMDA) is expected to be announcing its Q2 2025 earnings results before the market opens on Wednesday, August 13th. Analysts expect the company to announce earnings of $0.09 per share and revenue of $158.59 million for the quarter. Kamada has set its FY 2025 guidance at EPS.

Kamada (NASDAQ:KMDA) last issued its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported $0.07 EPS for the quarter, meeting the consensus estimate of $0.07. The business had revenue of $44.02 million during the quarter, compared to the consensus estimate of $154.06 million. Kamada had a net margin of 9.60% and a return on equity of 6.31%. On average, analysts expect Kamada to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Kamada Price Performance

Shares of NASDAQ:KMDA opened at $7.34 on Tuesday. The company has a market cap of $422.12 million, a price-to-earnings ratio of 25.31, a PEG ratio of 0.86 and a beta of 0.93. The firm has a 50 day simple moving average of $7.41 and a 200 day simple moving average of $7.05. Kamada has a one year low of $5.17 and a one year high of $9.15.

Institutional Investors Weigh In On Kamada

Large investors have recently modified their holdings of the company. Cubist Systematic Strategies LLC acquired a new stake in shares of Kamada during the first quarter worth $206,000. NewEdge Advisors LLC increased its position in shares of Kamada by 119.9% during the first quarter. NewEdge Advisors LLC now owns 51,661 shares of the biotechnology company’s stock worth $341,000 after buying an additional 28,165 shares during the period. Goldman Sachs Group Inc. acquired a new stake in shares of Kamada during the first quarter worth $497,000. Finally, Jane Street Group LLC acquired a new stake in shares of Kamada during the first quarter worth $582,000. 20.38% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Sidoti raised shares of Kamada to a “hold” rating in a research note on Thursday, May 8th. Wall Street Zen raised shares of Kamada from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 21st. Finally, Benchmark reaffirmed a “buy” rating and set a $15.00 price target on shares of Kamada in a research note on Thursday, May 15th.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.